Artemis Medicare (ARTEMISMED)
Fast GrowerFairStock Score: 33/100 — RISKY
Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹314.75 |
| Market Cap | ₹3,797.77 Cr |
| P/E Ratio | 137.45 |
| ROCE | 14.88% |
| ROE | 12.19% |
| Dividend Yield | 0.19% |
| Profit Growth | 44.98% |
| Debt/Equity | 0.28 |
| Sales Growth | 9.84% |
| Promoter Holding | 58.39% |
| 52-Week Range | ₹203.35 — ₹378.4 |
| Sector | Healthcare Services |
| Book Value | ₹59.05 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Let me look at Artemis Medicare as I would any business. It is a hospital operator, a sector I respect because demand for quality healthcare compounds for decades as incomes rise and demographics age. The company has grown sales at nearly 18% and profits at close to 20%, which is genuinely good. Return on equity is 12.19%, and ROCE is 14.88%; not mouth-watering, but respectable for an asset-heavy hospital business. I am pleased borrowed capital is moderate, with debt-equity only 0.31. Promoters own 58.39%, aligning their interests with mine. The Piotroski score of 7 suggests the recent financial condition is sound.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer